Literature DB >> 15237096

Calcitonin gene-related peptide (CGRP) antagonists: blockers of neuronal transmission in migraine.

Susan D Brain1.   

Abstract

The neuropeptide calcitonin gene-related peptide (CGRP) is a potent vasodilator that is contained in and released from sensory nerves. CGRP has been implicated in migraine, and the nonpeptide CGRP antagonist BIBN4096BS has been shown to be effective in clinical trials in migraine. To date, it has been largely assumed that the CGRP antagonist is effective due to its ability to block vasodilator activity. Goadsby and co-workers present data that now suggest that CGRP antagonists may also block neuronal transmission in migraine. Copyright 2004 Nature Publishing Group

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15237096      PMCID： PMC1575173          DOI： 10.1038/sj.bjp.0705806

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  15 in total

1.  Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists.

Authors:  K J Powell; W Ma; M Sutak; H Doods; R Quirion; K Jhamandas
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

Review 2.  Migraine--current understanding and treatment.

Authors:  Peter J Goadsby; Richard B Lipton; Michel D Ferrari
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

Review 3.  Deconstructing migraine headache into peripheral and central sensitization.

Authors:  R Burstein
Journal:  Pain       Date:  2001-01       Impact factor: 6.961

4.  RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor.

Authors:  L M McLatchie; N J Fraser; M J Main; A Wise; J Brown; N Thompson; R Solari; M G Lee; S M Foord
Journal:  Nature       Date:  1998-05-28       Impact factor: 49.962

5.  Alleviation of mechanical and thermal allodynia by CGRP(8-37) in a rodent model of chronic central pain.

Authors:  A D Bennett; K M Chastain; C E Hulsebosch
Journal:  Pain       Date:  2000-05       Impact factor: 6.961

6.  Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.

Authors:  H Doods; G Hallermayer; D Wu; M Entzeroth; K Rudolf; W Engel; W Eberlein
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

7.  Vasoactive peptide release in the extracerebral circulation of humans during migraine headache.

Authors:  P J Goadsby; L Edvinsson; R Ekman
Journal:  Ann Neurol       Date:  1990-08       Impact factor: 10.422

Review 8.  New therapeutic target in primary headaches - blocking theCGRP receptor.

Authors:  Lars Edvinsson
Journal:  Expert Opin Ther Targets       Date:  2003-06       Impact factor: 6.902

9.  The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats.

Authors:  P J Goadsby; L Edvinsson
Journal:  Ann Neurol       Date:  1993-01       Impact factor: 10.422

10.  A comparison of the actions of BIBN4096BS and CGRP(8-37) on CGRP and adrenomedullin receptors expressed on SK-N-MC, L6, Col 29 and Rat 2 cells.

Authors:  Debbie L Hay; Stephen G Howitt; Alex C Conner; Henri Doods; Marcus Schindler; David R Poyner
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739
View more
  3 in total

Review 1.  Clinical data on the CGRP antagonist BIBN4096BS for treatment of migraine attacks.

Authors:  Lars Edvinsson
Journal:  CNS Drug Rev       Date:  2005

2.  Critical role of calcitonin gene-related peptide receptors in cortical spreading depression.

Authors:  Alessandro Tozzi; Antonio de Iure; Massimiliano Di Filippo; Cinzia Costa; Stefano Caproni; Antonio Pisani; Paola Bonsi; Barbara Picconi; Letizia M Cupini; Serena Materazzi; Pierangelo Geppetti; Paola Sarchielli; Paolo Calabresi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-29       Impact factor: 11.205

Review 3.  Migraine Modulation and Debut after Percutaneous Atrial Septal Defect Closure: A Review.

Authors:  Charles Stevens Leger; Joseph F X DeSouza
Journal:  Front Neurol       Date:  2017-03-20       Impact factor: 4.003
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.